The fill rate for Tamiflu, the nation's most popular flu prescription drug, is nearly 100 percent higher than it was this time last year, but the drugmaker has said it has "sufficient supply."
The week ending Nov. 26 saw a fill rate of 1.02 percent, according to GoodRx data. Last year at this time, that figure was 0.5 percent.
Tamiflu's generic, oseltamivir, has been in short supply for weeks, according to the American Society of Health-System Pharmacists' drug shortage website. The maker of Tamiflu, Roche, told Becker's that, despite the surge, there is "sufficient supply" of the brand product.
"According to the CDC, flu antiviral medications, like Xofluza and Tamiflu, work when started within two days of getting sick," a Roche spokesperson told Becker's. "Therefore, we encourage pharmacies to keep flu antiviral medications on hand throughout the season and we stand ready to collaborate with wholesalers and pharmacies as they work to ensure uninterrupted patient access in pharmacies across the U.S."
Multiple states are reporting very high or high flu activity as the hospitalization rate surpasses the average set over the last 12 years. Demand for Tamiflu shows a trend proportional to this year's flu season kicking off stronger and earlier than expected, as the fill rate indicates an early spike.